Markers are CD14, CD15, CD24, CD45, CD59, CD64, CD235a (Glycophorin A), and FLAER. In validation studies, this assay was shown to detect RBC and granulocyte PNH clones with frequency down to 0.01%.
Useful for diagnosis of PNH (paroxysmal nocturnal hemoglobinuria) and monitoring response to therapy. Small PNH clones may also be identified in patients with aplastic anemia and MDS who may respond to immune modulation therapy. Also identifies patients at increased risk of developing overt PNH. This assay is consistent with International Clinical Cytometry Society (ICCS) Guidelines. NeoGenomics no longer performs PNH testing on bone marrow specimens.
- Peripheral blood: 1-2 mL EDTA preferred. Sodium heparin is acceptable. Lithium heparin or ACD (pale yellow/no gel separator) is not acceptable. Please provide a recent CBC report. Bone marrow specimens are also not acceptable.
- NY Clients: Please provide Date and Time of Collection and recent transfusion history.
Specimens should be received at NeoGenomics within 72 hours from collection to assure sample integrity and acceptable cell viability. Note: New York State samples must be received within 48 hours from collection per NYS requirements. Refrigerate specimen. Do not freeze. Use cold pack for transport, making sure cold pack is not in direct contact with specimen.